Agilent Technologies (NYSE:A – Get Rating) issued its quarterly earnings results on Monday. The medical research company reported $1.53 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.39 by $0.14, MarketWatch Earnings reports. The company had revenue of $1.85 billion for the quarter, compared to analyst estimates of $1.76 billion. Agilent Technologies had a net margin of 18.31% and a return on equity of 30.55%. The business’s revenue for the quarter was up 11.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.21 earnings per share. Agilent Technologies updated its Q1 guidance to $1.29-$1.31 EPS and its FY23 guidance to $5.61-$5.69 EPS.
Agilent Technologies Price Performance
A stock opened at $156.86 on Wednesday. The company has a market capitalization of $46.44 billion, a P/E ratio of 37.62, a PEG ratio of 2.65 and a beta of 1.06. Agilent Technologies has a twelve month low of $112.52 and a twelve month high of $162.62. The business has a 50 day simple moving average of $133.55 and a 200-day simple moving average of $128.29. The company has a current ratio of 1.94, a quick ratio of 1.41 and a debt-to-equity ratio of 0.54.
Agilent Technologies Increases Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 25th. Stockholders of record on Tuesday, January 3rd will be issued a $0.225 dividend. This is an increase from Agilent Technologies’s previous quarterly dividend of $0.21. This represents a $0.90 annualized dividend and a dividend yield of 0.57%. The ex-dividend date is Friday, December 30th. Agilent Technologies’s dividend payout ratio is presently 20.14%.
Institutional Investors Weigh In On Agilent Technologies
Several large investors have recently modified their holdings of the stock. Fred Alger Management LLC raised its stake in shares of Agilent Technologies by 2.9% during the third quarter. Fred Alger Management LLC now owns 4,757 shares of the medical research company’s stock worth $578,000 after purchasing an additional 136 shares during the last quarter. Synovus Financial Corp raised its position in Agilent Technologies by 2.3% in the first quarter. Synovus Financial Corp now owns 6,751 shares of the medical research company’s stock worth $895,000 after acquiring an additional 153 shares in the last quarter. Brinker Capital Investments LLC raised its position in Agilent Technologies by 2.2% in the first quarter. Brinker Capital Investments LLC now owns 10,216 shares of the medical research company’s stock worth $1,352,000 after acquiring an additional 218 shares in the last quarter. Geller Advisors LLC raised its position in Agilent Technologies by 18.5% in the first quarter. Geller Advisors LLC now owns 1,602 shares of the medical research company’s stock worth $212,000 after acquiring an additional 250 shares in the last quarter. Finally, B. Riley Wealth Advisors Inc. raised its position in Agilent Technologies by 5.8% in the third quarter. B. Riley Wealth Advisors Inc. now owns 5,086 shares of the medical research company’s stock worth $619,000 after acquiring an additional 278 shares in the last quarter.
Wall Street Analysts Forecast Growth
A has been the subject of a number of analyst reports. Evercore ISI boosted their price objective on Agilent Technologies from $140.00 to $155.00 in a research report on Tuesday. Cowen boosted their price objective on Agilent Technologies from $160.00 to $168.00 in a research report on Tuesday. Cowen boosted their price objective on Agilent Technologies from $160.00 to $168.00 in a research report on Tuesday. Robert W. Baird boosted their price objective on Agilent Technologies from $160.00 to $170.00 in a research report on Tuesday. Finally, Bank of America boosted their price objective on Agilent Technologies from $148.00 to $155.00 and gave the stock a “buy” rating in a research report on Wednesday, August 17th. Four analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Agilent Technologies currently has a consensus rating of “Moderate Buy” and an average target price of $157.00.
Agilent Technologies Company Profile
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies.
- Get a free copy of the StockNews.com research report on Agilent Technologies (A)
- After Nixing its 13% Dividend, Is Lumen Technologies Okay To Own?
- The Sell-Side Caps Gains In Dick’s Sporting Goods
- Cisco Systems Hopes Restructuring Cuts Costs to Drive Revenue
- Want to Get a 10% Dividend Yield, Look Here
- Stock-ing Stuffers: 3 Attractive Stocks Trading Around $10
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.